rasagiline has been researched along with Disease Models, Animal in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (25.81) | 29.6817 |
| 2010's | 19 (61.29) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, P; Chen, Z; Lan, Y; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, C; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Bayir, Y; Halici, Z; Kose, D; Tastan, TB; Ugan, RA; Un, H; Yayla, M | 1 |
| Brandi, V; Carbo, M; Colotti, G; Ilari, A; Morea, V; Pascarella, G; Polticelli, F; Staid, DS | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Date, AA; Kalaria, D; Kalia, Y; Patel, P; Patravale, V; Pol, A | 1 |
| Cronin, A; Grealy, M | 1 |
| Gao, CM; Yang, XL | 1 |
| Bhattacharya, SS; Calado, SM; Diaz-Corrales, FJ; Garcia-Delgado, AB; Valdés-Sánchez, L | 1 |
| Ahn, EH; Cao, X; Dhakal, S; Iuvone, PM; Kang, SS; Liu, X; Manfredsson, FP; Sandoval, IM; Ye, K; Zhang, Z | 1 |
| Berkovich, E; Brundin, P; Fitzer-Attas, C; Fog, K; Hickery, M; Kallunki, P; Petit, GH | 1 |
| Biton, IE; Dror, V; Eliash, S; Rehavi, M | 1 |
| Amit, T; Badinter, F; Bar-Am, O; Weinreb, O; Youdim, MB | 1 |
| Badrinarayanan, S; Boivin, L; Bousquet, M; Chabrat, A; Charest, J; Cicchetti, F; Cisbani, G; Drouin-Ouellet, J; Gibrat, C; Lagacé, M; Lavallée-Bourget, MH; Lebel, M; Lévesque, M; Saint-Pierre, M | 1 |
| Boger, HA; Cantwell, K; Granholm, AC; Hinson, VK; Ledreux, A | 1 |
| Cohen, S; Dror, V; Eliash, S; Rehavi, M | 1 |
| Amit, T; Kalfon, L; Mandel, SA; Reznichenko, L; Youdim, MB | 1 |
| Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB | 1 |
| Amit, T; Bar-Am, O; Prosolovich, K; Weinreb, O; Youdim, MB | 1 |
| Abassi, ZA; Amit, T; Awad, H; Bar-Am, O; Barac, YD; Binah, O; Blank, A; Kostin, S; Ovcharenko, E; Roguin, A; Schaper, J; Youdim, M | 1 |
| Barcia, E; Fernández, M; Fernández-Carballido, A; Negro, S; Slowing, K | 1 |
| Eigeldinger-Berthou, S; Enzmann, V; Lecaudé, S; Meier, C; Sarra, GM; Zulliger, R | 1 |
| Rascol, O | 1 |
| Arjmand, FM; Christianson, C; Dines, K; Hamlin, R; Huang, B; Meier-Davis, SR; Nagata, T; Shudo, J; Wen, J | 1 |
| Barcia, E; Fernández, M; Fernández-Carballido, A; Garcia, L; Negro, S; Slowing, K | 1 |
| Dallemagne, P; Demotes-Mainard, J; Guillon, J; Hébert, G; Jarry, C; Léger, JM; Lisowski, V; Rault, S; Thé, C; Vidaillac, C | 1 |
| Armentero, MT; Blandini, F; Blaugrund, E; Fancellu, R; Nappi, G | 1 |
| Blaugrund, E; Ludolph, AC; Malessa, S; Reuter, A; Waibel, S | 1 |
| Eilam, R; Eliash, S; Shteter, N | 1 |
| Blaugrund, E; Cohen, S; Fine, T; Litinetsky, L; Mayk, A; Nyska, A; Speiser, Z | 1 |
| Poewe, W; Stefanova, N; Wenning, GK | 1 |
| Breithaupt, W; Gerlach, M; Götz, ME; Kupsch, A; Oertel, WH; Riederer, P; Sautter, J; Schwarz, J; Youdim, MB | 1 |
1 review(s) available for rasagiline and Disease Models, Animal
| Article | Year |
|---|---|
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Disease Models, Animal; Humans; Indans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Protein Structure, Quaternary; Selegiline | 2010 |
30 other study(ies) available for rasagiline and Disease Models, Animal
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Mice; Mice, Inbred Strains; Microsomes, Liver; Molecular Structure; Peptide Fragments; Positron Emission Tomography Computed Tomography; Protein Aggregates; Rats; Structure-Activity Relationship; Zebrafish | 2020 |
A new approach to sepsis treatment by rasagiline: a molecular, biochemical and histopathological study.
Topics: Acute Lung Injury; Animals; Cecum; Disease Models, Animal; Indans; Ligation; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sepsis | 2022 |
Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Topics: Animals; Brain; Computational Biology; Corpus Striatum; Disease Models, Animal; GTP-Binding Proteins; Humans; Huntingtin Protein; Huntington Disease; Indans; Models, Molecular; Mutant Proteins; Neurons; Protein Conformation; Sumoylation; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases | 2019 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Biological Availability; Disease Models, Animal; Emulsions; Feasibility Studies; Humans; Hydrogels; Indans; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rabbits; Rats; Rotenone; Skin; Skin Tests | 2021 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
c‑Jun N‑terminal kinase 3 signalling serves a potential role as a biomarker for determining the pathogenesis of Parkinson's disease.
Topics: Animals; Biomarkers; Caspase 3; Disease Models, Animal; Down-Regulation; Immunohistochemistry; Indans; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 10; MPTP Poisoning; Severity of Illness Index; Up-Regulation | 2018 |
Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression.
Topics: Administration, Oral; Animals; Animals, Newborn; bcl-2-Associated X Protein; Disease Models, Animal; Disease Progression; Gene Expression; Indans; Mice, Transgenic; Neuroprotective Agents; Photoreceptor Cells; Proto-Oncogene Proteins c-bcl-2; Retina; Retinitis Pigmentosa; Vision, Ocular | 2018 |
α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cysteine Endopeptidases; Disease Models, Animal; Dopamine; Indans; Mice; Mice, Transgenic; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Topics: Age Factors; alpha-Synuclein; Animals; Disease Models, Animal; Humans; Indans; Memory, Short-Term; Mice; Mice, Transgenic; Monoamine Oxidase Inhibitors; Olfaction Disorders; Olfactory Bulb; Parkinson Disease; Smell | 2013 |
Rasagiline prevents neurodegeneration in thiamine deficient rats-a longitudinal MRI study.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Disease Progression; Indans; Kaplan-Meier Estimate; Lateral Ventricles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Organ Size; Pyrithiamine; Rats; Rats, Sprague-Dawley; Thalamus; Thiamine Deficiency | 2014 |
Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice.
Topics: Aging; Animals; Catecholamines; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Indans; Longitudinal Studies; Male; Maze Learning; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Neuroprotective Agents; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Swimming | 2015 |
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Indans; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurites; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders | 2015 |
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
Topics: Animals; Behavior, Animal; Benzylamines; Brain; Brain-Derived Neurotrophic Factor; Chaperonin 60; Cognition; Disease Models, Animal; Dopamine; Indans; Locomotion; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Norepinephrine; Parkinson Disease; Rats; Rats, Inbred F344 | 2016 |
Neuroprotection by rasagiline in thiamine deficient rats.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Indans; Kaplan-Meier Estimate; Male; Maze Learning; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Thiamine Deficiency | 2009 |
Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.
Topics: Animals; Antioxidants; Catechin; Cell Line; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Indans; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Neuroprotective Agents; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Treatment Outcome | 2010 |
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?
Topics: Acetylcysteine; Animals; Catalase; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Humans; Hydrogen Peroxide; Indans; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley | 2011 |
TVP1022 attenuates cardiac remodeling and kidney dysfunction in experimental volume overload-induced congestive heart failure.
Topics: Animals; Cardiotonic Agents; Caspase 3; Cytochromes c; Disease Models, Animal; Fibrosis; Glomerular Filtration Rate; Heart Failure; Hypertrophy; Indans; Kidney; Myocytes, Cardiac; Natriuretic Peptide, Brain; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Ventricular Remodeling | 2011 |
An effective novel delivery strategy of rasagiline for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Delayed-Action Preparations; Disease Models, Animal; Fluorodeoxyglucose F18; Indans; Injections, Intraperitoneal; Lactic Acid; Male; Microspheres; Multimodal Imaging; Parkinsonian Disorders; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Positron-Emission Tomography; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rotenone; Tomography, X-Ray Computed | 2011 |
Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.
Topics: Administration, Oral; Animals; Apoptosis; Blotting, Western; Cell Death; Disease Models, Animal; Immunohistochemistry; Indans; Mice; Mice, Transgenic; Neuroprotective Agents; Real-Time Polymerase Chain Reaction; Retinal Degeneration; Retinal Photoreceptor Cell Outer Segment | 2012 |
[Disease-modifying therapies in PD].
Topics: Animals; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Endpoint Determination; Humans; Indans; Parkinson Disease; Randomized Controlled Trials as Topic | 2010 |
Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Female; Humans; Indans; Melanoma; Mice; Mice, Nude; Monoamine Oxidase Inhibitors; Skin Neoplasms; Tissue Distribution; Transdermal Patch; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
Topics: Animals; Apoptosis; Behavior, Animal; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Humans; Indans; Lactic Acid; Male; Microspheres; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Rotenone | 2012 |
Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.
Topics: Animals; Disease Models, Animal; Indans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Pyrroles; Stereoisomerism; Structure-Activity Relationship | 2003 |
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Topics: Animals; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Indans; Male; Monoamine Oxidase Inhibitors; Motor Activity; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase | 2004 |
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; Indans; Mice; Mice, Transgenic; Riluzole; Superoxide Dismutase; Superoxide Dismutase-1; Survival Rate | 2004 |
Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Indans; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Paraventricular Hypothalamic Nucleus; Rats; Rats, Inbred SHR; Rats, Wistar; Third Ventricle; Treatment Outcome; Vasopressins | 2005 |
Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.
Topics: Animals; Brain Infarction; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Indans; Infarction, Middle Cerebral Artery; Male; Maze Learning; Nerve Degeneration; Neuroprotective Agents; Rats; Rats, Wistar; Recovery of Function; Time Factors; Treatment Outcome | 2007 |
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Indans; Mice; Mice, Transgenic; Motor Activity; Multiple System Atrophy; Myelin Proteolipid Protein; Neurons; Neuroprotective Agents; Nitro Compounds; Propionates; Psychomotor Performance; Tyrosine 3-Monooxygenase | 2008 |
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Immunohistochemistry; Indans; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Neostriatum; Neurons; Norepinephrine; Parkinsonian Disorders; Selegiline; Serotonin; Substantia Nigra | 2001 |